Norgine — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Norgine is a well-established, revenue-generating European pharmaceutical company with over a century of operations, specializing in gastroenterology and hepatology. The company has built a sustainable business model through strategic partnerships, licensing, and acquisitions, generating over €500 million in net product sales. With over 1,400 employees, Norgine reinvests its profits into innovative medicines and maintains a focused pipeline, positioning itself as a reliable partner in the specialty pharma landscape.

GastroenterologyHepatology

Technology Platform

Specialized commercial and development infrastructure for partnership-based acquisition and lifecycle management of small molecule drugs in gastroenterology and hepatology.

Opportunities

The growing prevalence of chronic GI and liver diseases presents a sustained market opportunity.

Norgine's established European commercial platform is attractive to innovators seeking a launch partner, enabling further portfolio expansion.

Potential exists to leverage its infrastructure into adjacent specialty therapeutic areas.

Risk Factors

Growth is dependent on successfully licensing or acquiring new products in a competitive environment.

Revenue is concentrated in European markets, exposing the company to regional pricing and regulatory pressures.

Integration and commercial execution risks exist for any new assets brought into the portfolio.

Competitive Landscape

Norgine competes with other European specialist pharma companies (e.g., Tillotts Pharma, Dr. Falk Pharma) and the specialty divisions of large pharmaceutical firms. Its differentiation lies in its focused therapeutic expertise, partnership-friendly infrastructure, and agility compared to larger, slower-moving competitors.

More companies in Small Molecule Drugs →More companies in Austria →